nucana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. while these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. utilising our proprietary protide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
Company profile
Ticker
NCNA
Exchange
Website
CEO
Hugh Griffith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NuCana BioMed Ltd
SEC CIK
NCNA stock data
Latest filings (excl ownership)
6-K
NuCana Announces Completion of ADS Ratio Change
16 Apr 24
6-K
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy
9 Apr 24
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
27 Mar 24
424B5
Prospectus supplement for primary offering
27 Mar 24
6-K
NuCana Announces Plan to Implement ADS Ratio Change
27 Mar 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
20 Mar 24
6-K
Unaudited Condensed Consolidated Statements of Operations
16 Nov 23
6-K
NuCana Announces Listing Transfer to Nasdaq Capital Market
13 Nov 23
6-K
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC
16 Oct 23
Latest ownership filings
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
27 Feb 24
SC 13G/A
Griffith Hugh
14 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
26 Jan 24
SC 13G/A
Griffith Hugh
13 Feb 23
SC 13G/A
Capital International Investors
13 Feb 23
SC 13G/A
BAILLIE GIFFORD & CO
23 Jan 23
SC 13D/A
Carlyle Group Inc.
11 Aug 22
SC 13D/A
Sofinnova Venture Partners VIII, L.P.
28 Feb 22
SC 13G/A
Capital Research Global Investors
11 Feb 22
SC 13G/A
Capital International Investors
11 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
50.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 7.81 bn |
Total shares | 26.42 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sofinnova Venture Partners VIII | 5.78 mm | $26.46 mm |
Sofinnova Investments | 5.60 mm | $3.42 bn |
Sofinnova Capital Vi FCPR | 4.98 mm | $15.04 mm |
Baillie Gifford & Co | 3.66 mm | $2.23 bn |
CG Carlyle Group Inc | 3.33 mm | $1.97 bn |
Scottish Enterprise | 1.88 mm | $8.43 mm |
Acadian Asset Management | 590.65 k | $358.00 k |
Renaissance Technologies | 355.93 k | $217.00 k |
Steward Partners Investment Advisory | 76.75 k | $46.82 mm |
Edmond De Rothschild Holding | 50.00 k | $30.45 mm |
News
NuCana Announces Completion Of 1-For-25 ADS Ratio Change
16 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
28 Mar 24
Press releases
NuCana Announces Completion of ADS Ratio Change
16 Apr 24
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
9 Apr 24
NuCana Announces Plan to Implement ADS Ratio Change
27 Mar 24
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
20 Mar 24